SGLT 2 inhibitors provide kidney, cardiovascular benefits for diabetes patients

Published On 2021-11-13 09:29 GMT   |   Update On 2021-11-13 09:29 GMT
Advertisement

In addition to lowering blood sugar levels, diabetes drugs called Sodium-glucose cotransporter 2 (SGLT2) inhibitors can provide kidney- and cardiovascular-related benefits for people with type 2 diabetes.

A recent study has found that such benefits are also experienced by individuals with type 1 diabetes. There is a significant risk reductions for cardiovascular disease and kidney failure with SGLT2 inhibitor treatment in type 1 diabetes, confirms study.

For more details, check out the full story on the link

SGLT2 Inhibitors May Protect Kidney And Heart In Adults With Type 1 Diabetes: Study

Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News